ESMO 2023 showcased several promising trials in the small-cell lung cancer space. A cancer that continues to send shivers down the spine of budding oncologists for decades. Today, we look at several different classes of drugs, the first being a novel immunotherapy agent, the second a well-known antibody-drug conjugate and the third a synthetic alkaloid analogue. Lurbinectedin and pembrolizumab, sacitizumab govitecan or toripalimab, while all difficult to say five times fast, may change the future of small cell lung cancer. Which is your drug of choice? Tune in to find out if you chose correctly!

Studies discussed in this episode. Subscription may be required

• EXTENTORCH (Toripalimab) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639076
• LUPER trial (Lurbinectedin + pembrolizumab)- https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638285
• Tropics-03 trial (sacituzumab govitecan) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638286

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.